Comparison of efficacy and safety of gabapentin and duloxetine in painful diabetic peripheral neuropathy: A systematic review and meta-analysis of randomized controlled trials

Link to article at PubMed

Int J Clin Pract. 2021 Jun 25:e14576. doi: 10.1111/ijcp.14576. Online ahead of print.

ABSTRACT

BACKGROUND: In patients with diabetes mellitus, painful diabetic peripheral neuropathy (PDPN) is a frequent complication and can cause poor quality of life. We compared the efficacy and safety of duloxetine with those of gabapentin in patients with PDPN through a systematic review and meta-analysis of randomized controlled trials.

MATERIALS AND METHODS: PubMed, Embase, and the Cochrane Library were searched for eligible studies published from database inception to January 2021. Visual Analog Scale [VAS], sleep interference score, Clinical Global Impression of Change [CGIC], Patient Global Impression of Change [PGIC], Diabetic Neuropathy Symptom [DNS] score, Diabetic Neuropathic Examination [DNE] score, Neuropathic Disability Score [NDS] and side effects were used to compare duloxetine and gabapentin in patients with PDPN.

RESULTS: Three eligible randomized controlled trials involving 290 patients were included. No significant differences were observed between patients receiving duloxetine and gabapentin with respect to VAS (mean change difference = -1.23, 95% CI, -6.09 to 3.62; P = 0.62), sleep interference score (mean change difference = 0.42, 95% CI, -0.15 to 1.00; P = 0.15), CGIC (mean difference = 0.04, 95% CI, -0.11 to 0.20; P = 0.60), and PGIC (mean difference= 0.24, 95% CI, -0.13 to 0.60; P = 0.21), DNS (mean change difference = 0.14, 95% CI, -0.35 to 0.63; P = 0.58). DNE (mean change difference = 0.26, 95% CI, -0.35 to 0.86; P = 0.41), NDS (mean change difference = 0.30, 95% CI, -0.02 to 0.63; P = 0.07).

CONCLUSIONS: No significant differences were observed in the efficacy of duloxetine and gabapentin when treating patients with PDPN.

PMID:34171158 | DOI:10.1111/ijcp.14576

Leave a Reply

Your email address will not be published.